Showing results (111-120 of 163) with videos related to
Sort By:
Pageof 17
Neurology|May 6, 2018
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomasAlberto Picca, Giulia Berzero, Franck Bielle, et al.European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomasAlberto Picca, Mehdi Touat, Lisa Belin, et al.EMBO Molecular Medicine|May 4, 2016
MET inhibition overcomes radiation resistance of glioblastoma stem-like cellsFrancesca De Bacco, Antonio D'Ambrosio, Elena Casanova, et al.Nature Cancer|February 2, 2023
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapySimona Migliozzi, Young Taek Oh, Mohammad Hasanain, et al.Ebiomedicine|August 31, 2019
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheresDean Nehama, Natalia Di Ianni, Silvia Musio, et al.Cancer Immunology Research|February 6, 2021
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic SignalingElisa Landoni, Giovanni Fucá, Jian Wang, et al.Journal of the National Cancer Institute|March 6, 2015
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomideManuela Cominelli, Salvatore Grisanti, Stefania Mazzoleni, et al.Neuro-Oncology|March 15, 2006
Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1Tiziana Piepoli, Cemile Jakupoglu, Wenli Gu, et al.Nature Communications|November 14, 2024
Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomesAndré Bortolini Silveira, Alexandre Houy, Olivier Ganier, et al.Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.Pageof 17